Device Trial Radar · NCT03807661
Percutaneous Deep Vein Arterialization Post-Market Study
Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Dec 11, 2019
Primary completion
Oct 9, 2023
Study completion Oct 28, 2024
Sponsor
- Lead sponsor
- LimFlow SANot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 17, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 21 years, up to 95 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this post-market study is to evaluate the safety and effectiveness of the LimFlow System in creating a below-the-knee arterio-venous fistula for venous arterialization in subjects with critical limb ischemia.
Conditions
- Critical Limb Ischemia
Interventions
Percutaneous deep vein arterializationProcedure
Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
LimFlow SystemDevice
Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
Primary outcomes
What the sponsor says the trial is designed to measure.
- Amputation-free SurvivalTime frame: Throughout one year
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
North Bristol NHS Trust
Bristol, United Kingdom
Glenfield Hospital
Leicester, United Kingdom
Royal Liverpool and Broadgreen University Hospitals NHS Trust
Liverpool, United Kingdom
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.